-

Tivic Health Announces Manufacturing Partnership With Microart

Agreement expected to reduce product manufacturing and shipping costs

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a commercial-phase health technology company focused on bioelectronic medicine, today announced it has entered into an agreement with Microart Services Inc., headquartered in Buffalo, New York, to manufacture, on a non-exclusive basis, certain components and sub-assemblies of the company’s current and future products.

“We expect that our new partnership with Microart will significantly reduce our product manufacturing and shipping costs,” explained Ryan Sabia, COO of Tivic Health. “We are pleased to secure highly advantaged pricing and increase scalability while maintaining the advantages of North American-based manufacturing.”

About Tivic

Tivic Health Systems, Inc. is a commercial-phase health technology company delivering non-invasive bioelectronic treatments that provide consumers with a choice in the treatment of inflammation and certain other related conditions. For more information visit https://tivichealth.com @TivicHealth.

Forward-Looking Statements

This press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: market and other conditions; the risks that the ongoing COVID-19 pandemic may disrupt Tivic’s business more severely than it has to date or more severely than anticipated; and unexpected costs, charges or expenses that reduce Tivic’s capital resources. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Tivic’s actual results to differ from those contained in the forward-looking statements, see Tivic’s filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 31, 2022, under the heading “Risk Factors,” as well as the company’s subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.

Contacts

Media Contact:
Cheryl Delgreco
Cheryl.Delgreco@tivichealth.com
617-429-6749

Investor Contact:
Hanover International, Inc.
ir@tivichealth.com

Tivic Health Systems, Inc.

NASDAQ:TIVC

Release Versions
$Cashtags
Hashtags

Contacts

Media Contact:
Cheryl Delgreco
Cheryl.Delgreco@tivichealth.com
617-429-6749

Investor Contact:
Hanover International, Inc.
ir@tivichealth.com

Social Media Profiles
More News From Tivic Health Systems, Inc.

Tivic Expands Intellectual Property Portfolio

FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced it is expanding its intellectual property portfolio with the recent filing of two additional patent applications with the United States Patent and Trademark Office. The first application applies to Tivic’s TLR5 agonist portfolio, which includes Entolimod and Entolasta. The patent titled “Immunomodulatory Pathway Modifying Agents and Uses of Same for Cancer Therapy” r...

Tivic Health to Report Third Quarter 2025 Financial Results on November 14th Via Conference Call and Webcast

FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced that it will report its third quarter results for 2025 via pre-recorded conference call and webcast on Friday, November 14, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 888-506-0062 International: 973-528-0011 Participant Access Code: 230582 Webcast Link https://www.webcaster5.com/Webcast/Page/2865/53145 About Tivic Health Systems, Inc. T...

Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23

FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced that CEO, Jennifer Ernst, will participate in the eighth annual Constellation Forum, a global conversation on Bioelectronic Medicine. She will join other leaders in the field to discuss the opportunities for advancing bioelectronic medicine. When: Thursday, Oct. 23, at 11:55 a.m. ET/8:55 a.m. PT Panel Title: Building a Big Tent Bioelectronic Medicine stands to...
Back to Newsroom